Smiths Medical Announces the ECRI Evaluation of the CADD®-Solis v4 Wireless Ambulatory Infusion System

Smiths Medical is a leading medical device manufacturer. Today they announced the release of the ECRI evaluation report for CADD®-Solis v4 with wireless communication Patient-Controlled Analgesic (PCA) and epidural infusion pump.

ECRI is an independent non-profit organization improving the safety, quality, and cost-effectiveness of care across all healthcare settings worldwide. The report highlights ECRI’s evaluation ratings, test results, and purchasing recommendations for the CADD®-Solis pump.

The CADD®-Solis v4 system is a continuation of Smiths Medical’s commitment to advance patient care and help improve patient outcomes through leading-edge technology.

The CADD®-Solis pump maintains the advantages of an ambulatory pump for patient mobility and provides a single system that effectively delivers IV PCA, epidural, peripheral nerve blocks and subcutaneous from pump to patient. For the hospital, the CADD®-Solis system is designed to enhance patient safety through “smart programming” (use of medication safety software) and reduce the risk of tubing misconnections while providing a comprehensive and intuitive user experience for the healthcare provider.

“Smiths Medical is committed to patient safety and adoption of smart infusion pumps,” said Nathan Walker, Director of Ambulatory Infusion at Smiths Medical. “The wireless bi-directional communication sets the foundation for integrating pain management data delivery directly into the patient records in the hospital’s Electronic Health Records (EHR auto-documentation), saving clinicians time charting and increasing documentation accuracy.”

For more information about the CADD®-Solis PCA and epidural pump and to request a copy of the report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”